Support program satisfaction under the microscope for lung disease patients
NCT ID NCT06912659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program, their quality of life, and any depression symptoms over 12 months. The goal is to understand the program's impact, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Evidenze Health Espana S.L.
Barcelona, 08005, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- AI reads lung scans to predict who will get worse
- How safe is bronchoscopy for ILD patients? new study aims to find out
- New approach to CPR talks may help patients and families feel heard
- Can a breath test predict lung scarring? new study seeks answers